1
|
Bessette L, Rahman P, Kelsall J, Purvis J, Rampakakis E, Lehman A, Rachich M, Nantel F, Marrache M, Asin Milan O. AB0357 INCIDENCE AND DETERMINANTS OF INFECTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB IN REAL-WORLD PRACTICE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAlthough biologic use in rheumatoid arthritis (RA) has a well-characterized infections risk factor, most studies evaluating this association were conducted on first-generation anti-tumor necrosis factor (TNFi) agents or in early years post-drug development (early 2000).ObjectivesTo (i) characterize the long-term incidence of infection in a real-world cohort of RA patients treated with subcutaneous golimumab (GLM) in Canadian routine care; (ii) assess the impact of infections on GLM retention, and (iii) explore factors associated with the risk of infection.MethodsBioTRAC registry was a prospective, multicenter study that collected real-world clinical, laboratory, safety and patient-reported data from TNFi naïve patients or treated with biologics for a period of <6 months before enrolment. This post-hoc analysis included patients with RA who initiated GLM treatment. The incidence density rates (IDR) of total serious (SI) and non-serious (NSI) infections were calculated for the overall follow-up (90 months) period as well as by 6-month interval. Time to first infection and time to treatment discontinuation were assessed with the Kaplan-Meier estimator of the survival function. Determinants of infection over time or within the first 6 months were explored using generalized estimating equation models and logistic regression, respectively.Results530 patients were included with a mean (SD) age of 57.7 (13.0) years and disease duration of 8.0 (8.3) years. Of these, 404 (76.2%) were females, 74 (14.0%) were treated with ≤15mg/week MTX, 280 (52.8%) with >15mg/week MTX, while 173 (32.6%) were not on MTX. In terms of corticosteroids (CS), 72 (13.6%) were treated with ≤5mg/day, 63 (11.9%) with >5mg/day, and 391 (73.8%) were not on CS. Diabetes (4.5%), pulmonary disease (8.9%), and renal disease (18.5%) were present.Over a mean follow-up duration of 27.0 months, the IDR for total infections, NSI, and SI was 35.10 events/100 PYs, 32.90 events/100 PYs, and 2.23 events/100 PYs. Median estimated time to first infection was 52.9 months (SI: 84.9 months; NSI: 55.1 months) (Table 1). The incidence of total infections was 44.0, 37.3, 35.1, 29.4, 31.1, 35.7, 19.3 and 7.4 events/100 PYs at 0-6 months, 6-12 months, 12-24 months, 24-36 months, 36-48 months, 48-60 months, 60-72 months, 72-84 months, respectively and no infections between 84-90 months. In terms of determinants, no significant associations were identified for the incidence of infections within the first 6 months. However, presence of pulmonary disease was identified as a significant determinant of total infections (OR [95%CI]: 2.19 [1.36-3.52]) and NSI (2.22 [1.35-3.66]) over time, while higher age (1.08 [1.00-1.26]) and high (≥5 mg/day) CS dose (7.25 [1.12-46.80]) were associated with significantly higher odds of SI. Incidence of SI (6.48 [1.16-36.13]), but not NSI, was associated with significantly higher odds of GLM discontinuation; additional predictors of discontinuation were increased baseline CDAI (1.06 [1.04-1.08]) and use of concomitant MTX at low dose (0.52 [0.30-0.91]) or high dose (0.71 [0.49-1.04]).Table 1.Incidence Density Rate (IDR) by Infection Type.Infection TypeIDR (Events/100 PYs)Median Time to 1st Infection (months)Total Infections35.152.9Non-serious Infections32.984.9Serious Infections2.255.1ConclusionThe infection rates reported with GLM in this cohort are low compared to the rates reported in earlier registry studies with TNFi. Changes in the characteristics of patients starting TNFi (lower disease activity, shorter disease duration, less exposure to CS) in recent years may explain the decreased risk of infection. Compared to the available literature, treatment with GLM was associated with relatively low infection rate. Most infections occurred during the first 6 months of treatment and decreased thereafter. Presence of pulmonary disease, higher age, and higher CS dose were identified as significant predictors of infections. SIs, but not NSIs, were associated with significantly higher odds of treatment discontinuation-TNFi.Disclosure of InterestsLouis Bessette Speakers bureau: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Gilead, Sandoz, Fresenius Kabi, Teva, Consultant of: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Gilead, Sandoz, Fresenius Kabi, Teva, Grant/research support from: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Gilead, Sandoz, Fresenius Kabi, Teva, Proton Rahman Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: Janssen and Novartis, John Kelsall: None declared, Jane Purvis: None declared, Emmanouil Rampakakis Consultant of: Janssen, Allen Lehman Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Meagan Rachich Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Francois Nantel Shareholder of: Johnson & Johnson, Employee of: Retiree from Janssen Pharmaceutical Companies of Johnson & Johnson, Marilise Marrache Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Odalis Asin Milan Shareholder of: Johnson & Johnson, Employee of: Employees of Janssen Pharmaceutical Companies of Johnson & Johnson
Collapse
|
2
|
Bhoi P, Bessette L, Bell M, Tkaczyk C, Nantel F, Maslova K. AB1040 Comparison of Adherence and Dosing Interval of Subcutaneous anti-TNF Biologics in Inflammatory Arthritis from A Canadian Administrative Database. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3760] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
3
|
Zummer M, Rahman P, Starr M, Kelsall J, Avina-Zubieta A, Baer P, Sholter D, Teo M, Rampakakis E, Psaradellis E, Osborne B, Maslova K, Nantel F, Lehman A, Tkaczyk C. FRI0467 Predictors of Early Minimal Disease Activity in PSA Patients Treated with Anti-TNF in A Real-World Registry. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Starr M, Haraoui B, Choquette D, Bessette L, Chow A, Baer P, Kapur S, Kelsall J, Teo M, Rampakakis E, Psaradellis E, Nantel F, Lehman A, Osborne B, Maslova K, Tkaczyk C. AB0220 What Proportion of Patients Fail To Achieve CDAI and SDAI Remission Based on Physician Global Assessment? An Analysis from A Prospective, Observational Registry. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
5
|
Bessette L, Kapur S, Zummer M, Starr M, Choquette D, Sheriff M, Olszynski W, Rampakakis E, Psaradellis E, Osborne B, Maslova K, Nantel F, Lehman A, Tkaczyk C. AB0661 Predictors of Response in Patients with Ankylosing Spondylitis Treated with Infliximab or Golimumab in A Real-World Setting. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Kelsall J, Choquette D, Rahman P, Arendse R, Teo M, Fortin I, Avina-Zubieta J, Rampakakis E, Psaradellis E, Maslova K, Osborne B, Tkaczyk C, Nantel F, Lehman A. FRI0421 What Is The Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond To Anti-TNF Treatment?: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Starr M, Zummer M, Choquette D, Haraoui B, Rahman P, Sheriff M, Rampakakis E, Psaradellis E, Osborne B, Lehman A, Maslova K, Nantel F, Tkaczyk C. AB0684 Gender Specific Differences in Ankylosing Spondylitis at Treatment Initiation in Patients Treated with Infliximab or Golimumab: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
8
|
Arendse R, Haraoui B, Choquette D, Kelsall J, Baer P, Sholter D, Bensen W, Bell M, Teo M, Rampakakis E, Psaradellis E, Osborne B, Tkaczyk C, Maslova K, Nantel F, Lehman A. FRI0579 What Is The Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF? Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Keystone E, Baer P, Olszynski W, Baker M, Haraoui B, Bensen W, Faraawi R, Rampakakis E, Sampalis J, Lehman A, Nantel F, Osborne B, Tkaczyk C, Maslova K. FRI0172 Primary and Secondary Non-Response in RA Patients Treated with An anti-TNF: An Analysis from A Prospective, Observational Registry. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Starr M, Zummer M, Choquette D, Haraoui B, Sholter D, Arendse R, Fortin I, Bessette L, Rahman P, Rampakakis E, Psaradellis E, Lehman A, Maslova K, Osborne B, Nantel F, Tkaczyk C. SAT0394 Impact of Disease Duration on Patient Reported and Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Anti-TNF: An Analysis from A Prospective, Observational Registry. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Arendse R, Rahman P, Avina-Zubieta J, Choquette D, Zummer M, Baker M, Stewart J, Fortin I, Teo M, Rampakakis E, Psaradellis E, Osborne B, Tkaczyk C, Maslova K, Nantel F, Lehman A. FRI0429 What Is The Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond To Anti-TNF Treatment?: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
Lathia U, Nantel F, Ewara E. SAT0611 The Impact of Adherence To Biologic Agents on Health Care Resource Utilization for Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Chow A, Bensen W, Arendse R, Keystone E, Baer P, Kelsall J, Olszynski W, Rodrigues J, Avina-Zubieta A, Baker M, Olszynski W, Bensen W, Baer P, Choquette D, Kapur S, Jaroszynska A, Sampalis J, Choquette D, Rampakakis E, Kapur S, Stewart J, Tkaczyk C, Sampalis J, Shawi M, Rampakakis E, Lehman A, Nantel F, Otawa S, Tkaczyk C, Lehman A. SAT0062 What is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and what are the Predictors of Progression to Unemployment? Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6199] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Rahman P, Zummer M, Olszynski W, Khraishi M, Sholter D, Faraawi R, Bensen W, Baker M, Chow A, Vaillancourt J, Sampalis J, Nantel F, Otawa S, Lehman A, Tkaczyk C, Shawi M. FRI0204 What is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Sholter D, Olszynski W, Baer P, Sheriff M, Dixit S, Chow A, Haraoui B, Choquette D, Kelsall J, Sampalis J, Rampakakis E, Nantel F, Tkaczyk C, Lehman A. SAT0338 Does Treatment Improve HAQ or Do Patients Adjust How They Do Things? An Exploration of the HAQ-DI Vs the HAQ-ADI Over Time. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
16
|
Faraawi R, Dixit S, Mulgund M, Bensen W, Kelsall J, Choquette D, Baker M, Fortin I, Sampalis J, Rampakakis E, Tkaczyk C, Lehman A, Nantel F. AB1163 Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Rahman P, Jovaisas A, Bensen W, Olszynski W, Jaroszynska A, Baer P, Sheriff M, Sholter D, Psaradellis E, Sampalis J, Nantel F, Otawa S, Lehman A, Tkaczyk C, Shawi M. THU0196 Is the Basdai Score Driven by Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF? Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Faraawi R, Joshi R, Bensen W, Choquette D, Olszynski W, Arendse R, Sheriff M, Rahman P, Sampalis J, Rampakakis E, Tkaczyk C, Nantel F. SAT0168 What is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? An Analysis from a Real-World Registry. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
Arendse R, Kelsall J, Avina-Zubieta A, Baer P, Rodrigues J, Jovaisas A, Fortin I, Sheriff M, Khraishi M, Rampakakis E, Sampalis J, Nantel F, Shawi M, Tkaczyk C, Otawa S, Lehman A. THU0365 Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Bensen W, Keystone E, Baer P, Rodrigues J, Avina-Zubieta A, Olszynski W, Choquette D, Kapur S, Sampalis J, Rampakakis E, Tkaczyk C, Shawi M, Lehman A, Nantel F, Otawa S. SAT0090 Exploring The Das: What is the Level of Agreement in the Classification of Remission and Low Disease Activity Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? An Analysis from a Prospective, Observational Registry. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Choquette D, Thorne C, Khraishi M, Fortin I, Arendse R, Chow A, Kelsall J, Baker M, Vaillancourt J, Sampalis J, Nantel F, Otawa S, Lehman A, Tkaczyk C, Shawi M. SAT0565 Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
22
|
Keystone E, Baer P, Avina-Zubieta A, Jaroszynska A, Rodrigues J, Arendse R, Sholter D, Starr M, Masetto A, Sampalis J, Rampakakis E, Tkaczyk C, Shawi M, Lehman A, Nantel F, Otawa S. FRI0036 What is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors? Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Baer P, Keystone E, Bensen W, Thorne C, Haraoui B, Choquette D, Arendse R, Kelsall J, Sheriff M, Sampalis J, Rampakakis E, Tkaczyk C, Shawi M, Lehman A, Nantel F, Otawa S. AB0304 What Proportion of Patients Fail to Achieve Das, Cdai, Sdai Remission Based on Patient Global assessment? An Analysis from a Prospective, Observational Registry. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Sholter D, Kelsall J, Arendse R, Avina-Zubieta A, Bensen W, Zummer M, Faraawi R, Dixit S, Khraishi M, Fortin I, Sampalis J, Psaradellis E, Nantel F, Tkaczyk C, Lehman A. SAT0557 Predictors of Response in Patients with Psoriatic Arthritis Treated with Anti-TNF in a Real-World Setting. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
25
|
Bensen W, Haraoui B, Thorne C, Keystone E, Zummer M, Fortin I, Faraawi R, Chow A, Arendse R, Baker M, Jones N, Rampakakis E, Sampalis J, Shawi M, Nantel F, Lehman A, Otawa S. FRI0047 Prediction of Remission by Patients and Physicians: Does the Doctor Know Best? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Bensen W, Kelsall J, Sheriff M, Jones N, Fortin I, Chow A, Shaikh S, Choquette D, Rampakakis E, Sampalis J, Nantel F, Shawi M, Otawa S, Lehman A. AB1060 Are There Gender-Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Bensen W, Thorne C, Baer P, Chow A, Arendse R, Baker M, Haraoui B, Jovaisas A, Sampalis J, Rampakakis E, Lehman A, Nantel F, Shawi M, Otawa S. SAT0071 Assessment of Rheumatoid Arthritis Disease Activity by Patients and Physicians: do Physicians Detect Improvement before the Patient Does? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Haraoui B, Sheriff M, Khraishi M, Starr M, Kelsall J, Baker M, Arendse R, Dixit S, Bensen W, Baer P, Faraawi R, Rampakakis E, Sampalis J, Otawa S, Lehman A, Nantel F, Shawi M. THU0241 Predictors of Acr/Eular Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: an Analysis from the Prospective, Observational Registry, Biotrac. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Rahman P, Shaikh S, Starr M, Bensen W, Choquette D, Olszynski W, Sheriff M, Zummer M, Rampakakis E, Sampalis J, Lehman A, Otawa S, Nantel F, Letourneau V, Shawi M. AB0760 Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: an Analysis from the Prospective, Observational Registry, Biotrac. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Keystone E, Baer P, Haraoui B, Avina-Zubieta J, Chow A, Sholter D, Choquette D, Rampakakis E, Sampalis J, Nantel F, Lehman A, Shawi M, Otawa S. AB0236 What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Sholter D, Bensen W, Choquette D, Fortin I, Arendse R, Kelsall J, Sheriff M, Faraawi R, Rodrigues J, Zummer M, Dixit S, Starr M, Rampakakis E, Sampalis J, Nantel F, Shawi M, Otawa S, Lehman A. AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Kelsall J, Jovaisas A, Rahman P, Sholter D, Starr M, Bensen W, Sheriff M, Olszynski W, Zummer M, Faraawi R, Chow A, Kapur S, Rampakakis E, Sampalis J, Nantel F, Otawa S, Shawi M, Lehman A. AB1059 Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in A Canadian Setting. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Jovaisas A, Starr M, Choquette D, Zummer M, Arendse R, Sholter D, Faraawi R, Rodrigues J, Kapur S, Rampakakis E, Sampalis J, Nantel F, Lehman A, Otawa S, Shawi M. AB0302 Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in A Real-World Setting. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Haraoui B, Jovaisas A, Bensen W, Faraawi R, Kelsall J, Dixit S, Rodrigues J, Sheriff M, Rampakakis E, Sampalis J, Lehman A, Otawa S, Nantel F, Shawi M. SAT0035 Impact of Corticosteroid Use on Remission Sustainability and Infection Rates among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on A Real-World Population. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
35
|
Arendse R, Bensen W, Chow A, Rodrigues J, Dixit S, Sholter D, Baer P, Baker M, Choquette D, Fortin I, Jovaisas A, Rampakakis E, Sampalis J, Nantel F, Otawa S, Shawi M, Lehman A. SAT0083 Does Specific Joint Involvement in Rheumatoid Arthritis Patients PREDICT Patient Reported Outcomes? Implications for Clinical Practice. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Thorne C, Bensen W, Dixit S, Faraawi R, Sholter D, Sheriff M, Baer P, Choquette D, Haraoui B, Jovaisas A, Rampakakis E, Sampalis J, Shawi M, Nantel F, Lehman A, Otawa S. AB0228 Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of the Biologic Treatment Registry Site. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Sholter D, Rahman P, Avina-Zubieta J, Kelsall J, Arendse R, Khraishi M, Shaikh S, Bensen W, Rampakakis E, Sampalis J, Nantel F, Shawi M, Otawa S, Lehman A. THU0438 Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Rahman P, Choquette D, Khraishi M, Bensen W, Shaikh S, Sholter D, Sheriff M, Rampakakis E, Sampalis J, Nantel F, Otawa S, Lehman A, Shawi M. SAT0363 Validation of the Ankylosing Spondylitis Disease Activity SCORE (ASDAS) and Effectiveness of Infliximab in the Treatment of Ankylosing Spondylitis over 4 Years. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Choquette D, Bensen W, Faraawi R, Nantel F. AB0382 Factors Associated with the Incidence of Infusion Reactions to Infliximab: Results from “Remitrac Infusion”, A Prospective Real-World Community Registry. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Keystone E, Thorne C, Starr M, Rodrigues J, Baer P, Arendse R, Avina-Zubieta J, Choquette D, Rampakakis E, Sampalis J, Shawi M, Nantel F, Lehman A, Otawa S. THU0247 What is More Predictive of Achieving Remission at 12 Months: the Percentage of Baseline Improvement or the Actual Disease State Achieved? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Rahman P, Choquette D, Bensen W, Khraishi M, Shaikh S, Arendse R, Fortin I, Chow A, Sholter D, Psaradellis E, Sampalis J, Otawa S, Nantel F, Lehman A, Shawi M. AB0761 Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in PSA Patients Treated with Anti-TNF in A Real-World Setting. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2383] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Choquette D, Sholter D, Fortin I, Starr M, Thorne C, Baker M, Arendse R, Baer P, Zummer M, Rodrigues J, Sheriff M, Rampakakis E, Sampalis J, Nantel F, Lehman A, Otawa S, Shawi M. AB0234 Differential Relative Contribution of Individual Components on DAS28 over Time. an Analysis from the Prospective, Observational Registry, Biotrac. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Choquette D, Starr M, Khraishi M, Bensen W, Shaikh S, Rodrigues J, Sholter D, Sheriff M, Vaillancourt J, Sampalis J, Lehman A, Otawa S, Nantel F, Shawi M. SAT0336 Change over Time in the Profile of Ankylosing Spondylitis Patients Treated with Infliximab in A REAL World Routine Care. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Haraoui B, Jovaisas A, Bensen WG, Faraawi R, Kelsall J, Dixit S, Rampakakis E, Sampalis JS, Nantel F, Otawa S, Lehman AJ, Shawi M. THU0179 Corticosteroid Use in Rheumatoid Arthritis Patients on Infliximab: Treatment Implications Based on a Real-World Canadian Population. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Bensen WG, Jovaisas A, Thorne C, Baer P, Khraishi M, Dixit S, Choquette D, Starr M, Fortin I, Sholter D, Rampakakis E, Sampalis JS, Lehman AJ, Nantel F, Shawi M, Otawa S. SAT0035 Variability in the Classification of Remission among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Thorne C, Khraishi M, Haraoui B, Rodrigues J, Jovaisas A, Choquette D, Dixit S, Sholter D, Baer P, Sheriff M, Rampakakis E, Sampalis JS, Nantel F, Lehman A, Shawi M, Otawa S. THU0131 Correlation of Individual HAQ Questions with Outcome Measures in Rheumatoid Arthritis: Implications for Instrument Reduction. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Choquette D, Thorne C, Kelsall J, Zummer M, Starr M, Sheriff M, Bensen WG, Chow A, Baer P, Rampakakis E, Sampalis JS, Nantel F, Lehman AJ, Otawa S, Shawi M. THU0142 Methotrexate Use at Infliximab Initiation and Impact on Treatment Outcomes: An Analysis from the Canadian Registry, Biotrac. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Arendse R, Starr M, Rahman P, Kelsall J, Baker M, Bensen W, Thorne C, Baer P, Choquette D, Fortin I, Rampakakis E, Sampalis J, Otawa S, Shawi M, Nantel F, Lehman AJ. SAT0551 What is the Real World Relationship between Patient-Reported Pain or Patient Global Assessment and Disease Activity Indices in Rheumatoid Arthritis? An Analysis from the Prospective, Observational Registry, Biotrac. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Bouvier M, Nantel F, Valiquette M, Moffett S, Mouillac B. Le récepteur β2-adrénergique. Un modèle d'étude des mécanismes moléculaires de la désensibilisation. ACTA ACUST UNITED AC 2013. [DOI: 10.4267/10608/2293] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Daull P, Lepage R, Benrezzak O, Cayer J, Beaudoin M, Belleville K, Blouin A, Sirois P, Nantel F, Jeng AY, Battistini B. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol 2006; 29:183-202. [PMID: 16707327 DOI: 10.1080/01480540600566717] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
CGS 35601 is a triple vasopeptidase inhibitor (VPI) of angiotensin-converting enzyme, neutral endopeptidase, and endothelin-converting enzyme-1 with respective IC50 values of 22, 2, and 55 nM. We characterized the safety profile and toxicity of escalating doses of CGS 35601 over a 20-day period in chronically instrumented, unrestrained, conscious, male, spontaneously hypertensive rats (SHR). Once instrumented with an arterial catheter, the SHR were placed in metabolic cages allowing daily assessment of hemodynamics and blood sampling for biochemical and hematological measurements. After a 7-day stabilization period, the SHR were divided into 2 groups: Gr. 1, (n = 13 to 18) receiving CGS 35601 at 0.01, 0.1, 1 and 5 mg kg(-1) day(-1) (continuous i.a. infusion) for 5 consecutive days/dose, followed by a 5-day washout; and Gr. 2, (n = 10) receiving vehicle (saline). The highest dose of CGS 35601 dose-dependently reduced MABP from 156 +/- 4 up to 94 +/- 5 mm Hg, whereas heart rate, metabolic, electrolytic, and hematological profiles, growth, diuresis, and renal activity were unaffected, and no hepatic or liver toxicities were observed. These results suggest that this novel triple VPI presents no safety concerns at this stage and may become of interest for the treatment of hypertension and other cardiovascular disorders. Long-term chronic experiments are needed to assess possible angioedema and increases in vascular permeability.
Collapse
Affiliation(s)
- P Daull
- Department of Medicine, Laval University, Laval Hospital Research Center, Quebec Heart and Lung Institute, Ste-Foy, QC, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|